Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- IVUS-CHIP and OPTIMAL: IVUS-Guided vs. Angiography-Guided PCIWhen compared with angiography-guided PCI, IVUS-guided PCI was found to be not superior in patients with complex coronary arteries according to results from the IVUS-CHIP trial or in patients with unprotected left main coronary artery disease (LM-CAD) according to results from the OPTIMAL trial. Both trials were presented in a Late-Breaking Clinical Trial session at […]
- SirPAD: Sirolimus-Coated vs. Uncoated Balloons in Angioplasty For Infrainguinal Artery DiseaseFor patients with symptomatic infrainguinal artery disease, angioplasty with a sirolimus-coated balloon, compared with an uncoated balloon, reduced major adverse limb events (MALE) at one year, according to the SirPAD trial results presented during a Late-Breaking Clinical Trial session at ACC.26 and simultaneously published in NEJM.
- DKCRUSH VIII: IVUS-Guided PCI Superior to Angiography-Guided PCI in Complex Coronary LesionsWhen using the two-stent double-kissing (DK) crush technique for PCI to treat complex coronary artery bifurcation lesions, IVUS-guided PCI was associated with a greater reduction in target vessel failure compared to angiography-guided PCI, according to the DKCRUSH VIII trial presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in […]
- IMPEDANCE-HFPEF: Early Noninvasive Detection of Lung Fluid Reduces Death, HospitalizationA noninvasive device used to monitor early fluid accumulation in the lungs of patients with heart failure with preserved ejection fraction (HFpEF) substantially reduced HF hospitalizations and mortality, according to results from the IMPEDANCE-HFPEF trial presented during ACC.26.
- CORALreef AddOn: Novel PCSK9 Inhibitor Reduces LDL-C in Patients Not Meeting GoalsThe novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults already being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to results from the CORALreef AddOn trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC.
Become an ACC Member Today!
Already a Member?
Access your profile | Renew your membership | Personalize your ACC.org







Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: